Expert Opinion on Pharmacotherapy
Volume 21, 2020 - Issue 1
Open access
4,645
Views
4
CrossRef citations to date
0
Altmetric
Original Research
Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin
Tomoko Hayashia Medical Division, Novartis Pharma K.K., Tokyo, JapanCorrespondence[email protected]
View further author information
, View further author information
Hiroki Murayamaa Medical Division, Novartis Pharma K.K., Tokyo, JapanView further author information
, Yohei Shinfukub Regulatory Office Japan, Novartis Pharma K.K., Tokyo, JapanView further author information
, Tomoko Taniguchib Regulatory Office Japan, Novartis Pharma K.K., Tokyo, JapanView further author information
, Isao Tsumiyamac Japan Development, Novartis Pharma K.K., Tokyo, JapanView further author information
& Naotsugu Oyamaa Medical Division, Novartis Pharma K.K., Tokyo, JapanView further author information
Pages 121-130
|
Received 07 Jun 2019, Accepted 23 Oct 2019, Published online: 05 Nov 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.